Trump administration cancels $766 million Moderna contract to fight pandemic flu

The Trump administration has canceled $766 million in funding awarded to Moderna for the development of an mRNA-based vaccine (mRNA-1018) targeting potential pandemic influenza viruses, including H5N1 bird flu, despite positive interim results from an early-stage trial showing a robust immune response and safety profile. The funding, awarded through BARDA in July 2024 and January, was intended to support late-stage clinical trials to determine the vaccine's efficacy; the cancellation introduces uncertainty despite ongoing concerns about the potential for bird flu to mutate and trigger a human pandemic.

Analysis

The Trump administration's decision to cancel $766 million in funding awarded through the Biomedical Advanced Research and Development Authority (BARDA) to Moderna Inc. for its pandemic influenza vaccine, mRNA-1018, introduces significant uncertainty for this specific development program. The rescinded funds, comprising $176 million awarded in July 2024 and $590 million in January, were notably intended to support a late-stage clinical trial to determine the vaccine's efficacy against potential pandemic viruses, including the H5N1 bird flu. This cancellation occurred despite Moderna's recent announcement of positive interim results from an early-stage trial of mRNA-1018, which involved 300 healthy adults and indicated a robust immune response and favorable safety profile against an H5 bird flu virus. The action is contextualized by Health Secretary Robert F. Kennedy Jr.'s expressed skepticism regarding mRNA vaccines, a technology pivotal to the rapid Covid-19 vaccine rollout. The development is particularly salient given ongoing concerns about H5N1's spillover into U.S. cattle, with at least 70 human infections and one death reported, and scientific apprehension that viral mutations could enhance its transmissibility or virulence in humans, potentially leading to a pandemic.

Key Decisions for Investors

• Investors should evaluate the direct financial impact of the $766 million funding withdrawal on Moderna's projected R&D expenditure for its pandemic influenza program and assess the increased risk to the mRNA-1018 development timeline and its path to potential market entry.
• Consider the heightened uncertainty surrounding future government support for Moderna's mRNA-based pandemic preparedness initiatives, balanced against the scientific validation from the positive early-stage trial data for mRNA-1018.
• Monitor Moderna's strategic responses to this funding gap, such as potential internal reallocation of resources, pursuit of alternative funding sources, or adjustments to its pandemic vaccine pipeline, while also tracking the epidemiological evolution of H5N1 and any shifts in public health policy that could influence demand or funding for related vaccines.